Home › Atopic Dermatitis (Eczema) › Illinois
Atopic Dermatitis (Eczema) clinical trials in Illinois
10 studies for Atopic Dermatitis (Eczema) are looking for participants at sites in Illinois.
Cities in Illinois
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Sneeze, Wheeze, & Itch Associates, LLC- Site Number : 8400029, Normal
- Rosalind Franklin University of Medicine and Science- Site Number: 8400056, North Chicago
RecruitingObservational study
Ages 12 and older · All sexes · Updated Sep 29, 2026 · NCT07290803Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Chicago
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT07298395A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Skokie
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07003425A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Endeavor Health, Skokie
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Aug 28, 2026 · NCT07599813A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 2, Rolling Meadows
RecruitingPhase 2
Ages 18 to 74 · All sexes · Updated Aug 12, 2026 · NCT07037901A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Northwestern University Feinberg School of Medicine /ID# 265117, Chicago
- Sneeze Wheeze & Itch Associates /ID# 267238, Normal
RecruitingPhase 3
Ages 2 to 11 · All sexes · Updated Aug 6, 2026 · NCT06461897A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- DeNova Research /ID# 264513, Chicago
- Northwestern University Feinberg School of Medicine /ID# 264983, Chicago
RecruitingPhase 3
Ages 18 to 63 · All sexes · Updated Jul 6, 2026 · NCT06389136Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
- Northwestern University Feinberg School of Medicine: Department of Dermatology, Chicago
RecruitingPhase 1
Ages 6 and older · All sexes · Updated Jul 2, 2026 · NCT06504160Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
- Lurie Children's Hospital/Northwestern University, Chicago
RecruitingPhase 4
Ages 6 to 17 · All sexes · Updated Apr 27, 2026 · NCT05042258Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 7058, Chicago
RecruitingObservational study
Ages 12 and older · All sexes · Updated Mar 13, 2026 · NCT06988605From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.